» Articles » PMID: 34809637

Risk of Bias in Observational Studies Using Routinely Collected Data of Comparative Effectiveness Research: a Meta-research Study

Overview
Journal BMC Med
Publisher Biomed Central
Specialty General Medicine
Date 2021 Nov 23
PMID 34809637
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To assess the completeness of reporting, research transparency practices, and risk of selection and immortal bias in observational studies using routinely collected data for comparative effectiveness research.

Method: We performed a meta-research study by searching PubMed for comparative effectiveness observational studies evaluating therapeutic interventions using routinely collected data published in high impact factor journals from 01/06/2018 to 30/06/2020. We assessed the reporting of the study design (i.e., eligibility, treatment assignment, and the start of follow-up). The risk of selection bias and immortal time bias was determined by assessing if the time of eligibility, the treatment assignment, and the start of follow-up were synchronized to mimic the randomization following the target trial emulation framework.

Result: Seventy-seven articles were identified. Most studies evaluated pharmacological treatments (69%) with a median sample size of 24,000 individuals. In total, 20% of articles inadequately reported essential information of the study design. One-third of the articles (n = 25, 33%) raised some concerns because of unclear reporting (n = 6, 8%) or were at high risk of selection bias and/or immortal time bias (n = 19, 25%). Only five articles (25%) described a solution to mitigate these biases. Six articles (31%) discussed these biases in the limitations section.

Conclusion: Reporting of essential information of study design in observational studies remained suboptimal. Selection bias and immortal time bias were common methodological issues that researchers and physicians should be aware of when interpreting the results of observational studies using routinely collected data.

Citing Articles

Causal associations between dietary habits and liver cancer risk: a two-sample Mendelian randomization study.

Hu W, Sun J, Liu C Discov Oncol. 2025; 16(1):120.

PMID: 39909996 PMC: 11799489. DOI: 10.1007/s12672-025-01885-w.


Methodological challenges using routine clinical care data for real-world evidence: a rapid review utilizing a systematic literature search and focus group discussion.

Pfaffenlehner M, Behrens M, Zoller D, Ungethum K, Gunther K, Rucker V BMC Med Res Methodol. 2025; 25(1):8.

PMID: 39810151 PMC: 11731536. DOI: 10.1186/s12874-024-02440-x.


Characteristics of non-randomised studies of drug treatments: cross sectional study.

Yaacoub S, Porcher R, Pellat A, Bonnet H, Tran V, Ravaud P BMJ Med. 2024; 3(1):e000932.

PMID: 39574419 PMC: 11579539. DOI: 10.1136/bmjmed-2024-000932.


Review of the target trial methodological approach on treatment effect estimates in kidney failure: protocol for a systematic assessment.

Pinter J, Tunnicliffe D, Karunikaikumar P, Anastasiadis A, Hills R Syst Rev. 2024; 13(1):280.

PMID: 39543770 PMC: 11566441. DOI: 10.1186/s13643-024-02672-4.


Conducting observational analyses with the target trial emulation approach: a methodological systematic review.

Simon-Tillaux N, Martin G, Hajage D, Scheifer C, Beydon M, Dechartres A BMJ Open. 2024; 14(11):e086595.

PMID: 39532374 PMC: 11574403. DOI: 10.1136/bmjopen-2024-086595.


References
1.
McHugh M . Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012; 22(3):276-82. PMC: 3900052. View

2.
Rea F, Corrao G, Merlino L, Mancia G . Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. Eur Heart J. 2018; 39(40):3654-3661. DOI: 10.1093/eurheartj/ehy420. View

3.
Kim N, Han K, Choi J, Lee J, Kim S . Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. BMJ. 2019; 366:l5125. PMC: 6763755. DOI: 10.1136/bmj.l5125. View

4.
Gershman B, Guo D, Dahabreh I . Using observational data for personalized medicine when clinical trial evidence is limited. Fertil Steril. 2018; 109(6):946-951. DOI: 10.1016/j.fertnstert.2018.04.005. View

5.
Rosenberg E, Dufort E, Udo T, Wilberschied L, Kumar J, Tesoriero J . Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA. 2020; 323(24):2493-2502. PMC: 7215635. DOI: 10.1001/jama.2020.8630. View